Alzamend Neuro Lands $7.5M Lifeline From an Affiliate Lender — But Can Convertible Preferred Stock Save a Company Worth Less Than the Cash It Just Raised?

Shares of Alzamend Neuro (ALZN) jumped 7.5% to $1.44 after the clinical-stage biotech disclosed a financing deal that dwarfs its own market value — raising immediate questions about survival, dilution, and who really benefits.

$7.5 Million in Hand, but the Company Is Worth Roughly $5 Million. Alzamend entered into an agreement with Ault Lending to purchase up to $25 million of Series D Convertible Preferred Stock, closing the initial $7.5 million tranche on July 31.

With only about 3.8 million shares outstanding and a recent market cap around $4.3 million, the gross proceeds from just the first tranche exceed the company's entire public equity value. That's a red flag for existing shareholders: it signals how desperately the cash was needed.

The "Going Concern" Clock Was Ticking. Alzamend issued a "substantial doubt" warning about its ability to continue operating in its Q3 2026 earnings report, released in March 2026.

At the time, the company had just $2.7 million in cash against $5.3 million in liabilities. The new funding buys time — but not certainty. The deal is structured across 17 tranche closings, with the remaining $15 million targeted in roughly monthly $1 million installments over about 15 months, meaning most of the headline figure is conditional and far off.

Conversion Terms Could Crush Common Shareholders. The preferred shares convert into common stock at 80% of the lowest closing bid over the prior five trading days, with a $2.00 cap and a $0.2668 floor. That built-in 20% discount means Ault Lending — an affiliate of the company — gets shares cheaper than any public buyer. At today's $1.44, conversion would price around $1.07–$1.15, creating massive potential dilution. Each tranche mints new common shares that shrink existing holders' ownership.

The Buyer Is an Insider, Not an Independent Validator. The purchaser is an affiliate of the company.

Ault Lending also secured a three-year right of first refusal and 33.33% participation rights in any future equity deals, locking in control over Alzamend's financing future. This isn't arm's-length validation from an outside investor betting on the science — it's a related party extending a lifeline on highly favorable terms. The financing is intended to support clinical programs, including a next-generation lithium product and a Phase I/IIA Alzheimer's vaccine trial. Whether those programs ever produce revenue remains years away. Investors cheering the headline number should read the fine print.